Novo Nordisk trial suggests semaglutide could transform childhood obesity treatment

A new phase 3 trial indicates that semaglutide, a drug developed by Novo Nordisk, may enable some children with severe obesity to lose enough weight to fall below clinical thresholds, raising both hope and questions about early intervention. A new…













